[go: up one dir, main page]

AU2001248699A1 - A pharmaceutical composition and method of treatment of diseases of cognitive dysfuntion in a mammal - Google Patents

A pharmaceutical composition and method of treatment of diseases of cognitive dysfuntion in a mammal

Info

Publication number
AU2001248699A1
AU2001248699A1 AU2001248699A AU4869901A AU2001248699A1 AU 2001248699 A1 AU2001248699 A1 AU 2001248699A1 AU 2001248699 A AU2001248699 A AU 2001248699A AU 4869901 A AU4869901 A AU 4869901A AU 2001248699 A1 AU2001248699 A1 AU 2001248699A1
Authority
AU
Australia
Prior art keywords
dysfuntion
cognitive
mammal
diseases
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001248699A
Inventor
Jotham Wadsworth Coe
Edmund Patrick Harrigan
Brian Thomas O'neill
Steven Bradley Sands
Eric Jacob Watsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2001248699A1 publication Critical patent/AU2001248699A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001248699A 2000-05-09 2001-04-24 A pharmaceutical composition and method of treatment of diseases of cognitive dysfuntion in a mammal Abandoned AU2001248699A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20279900P 2000-05-09 2000-05-09
US60202799 2000-05-09
PCT/IB2001/000681 WO2001085145A2 (en) 2000-05-09 2001-04-24 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal

Publications (1)

Publication Number Publication Date
AU2001248699A1 true AU2001248699A1 (en) 2001-11-20

Family

ID=22751325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001248699A Abandoned AU2001248699A1 (en) 2000-05-09 2001-04-24 A pharmaceutical composition and method of treatment of diseases of cognitive dysfuntion in a mammal

Country Status (16)

Country Link
US (2) US20010036949A1 (en)
EP (1) EP1280554A2 (en)
JP (1) JP2003532670A (en)
AR (1) AR028426A1 (en)
AU (1) AU2001248699A1 (en)
BR (1) BR0110487A (en)
CA (1) CA2409720A1 (en)
EC (1) ECSP014065A (en)
GT (1) GT200100075A (en)
MX (1) MXPA02011051A (en)
PA (1) PA8516701A1 (en)
PE (1) PE20011256A1 (en)
SV (1) SV2002000440A (en)
TN (1) TNSN01068A1 (en)
UY (1) UY26693A1 (en)
WO (1) WO2001085145A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
EP1311272B1 (en) 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
WO2002085843A2 (en) * 2001-04-20 2002-10-31 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
US20040006092A1 (en) * 2001-08-31 2004-01-08 Neurochem, Inc. Amidine derivatives for treating amyloidosis
US20040092427A1 (en) * 2002-09-25 2004-05-13 Anil Gulati Method and composition for treating alzheimer's disease and dementias of vascular origin
US8030300B2 (en) * 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
CN100549004C (en) 2003-10-01 2009-10-14 阿得罗公司 Spirocyclic heterocyclic derivatives and methods of use thereof
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005112946A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
EP1749017A2 (en) * 2004-05-27 2007-02-07 MIGENIX Corp. Compounds and methods for cytoprotection
JP2009506069A (en) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP2258358A3 (en) * 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007294968A1 (en) 2006-09-12 2008-03-20 Adolor Corporation Use of N-containing spirocompounds for the enhancement of cognitive function
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
FR2931677B1 (en) * 2008-06-02 2010-08-20 Sanofi Aventis ASSOCIATION OF A PARTIAL NICOTINIC RECEPTOR AGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR, COMPOSITION CONTAINING THE SAME AND USE THEREOF IN THE TREATMENT OF COGNITIVE DISORDERS
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8349376B1 (en) 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2012142039A1 (en) * 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
JP6440625B2 (en) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Methods and compositions for treating schizophrenia
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
HK1251980B (en) 2015-05-22 2020-07-10 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
WO2001085145A8 (en) 2001-12-13
MXPA02011051A (en) 2003-03-10
AR028426A1 (en) 2003-05-07
TNSN01068A1 (en) 2005-11-10
BR0110487A (en) 2003-04-01
WO2001085145A2 (en) 2001-11-15
US20010036949A1 (en) 2001-11-01
EP1280554A2 (en) 2003-02-05
WO2001085145A3 (en) 2002-06-13
JP2003532670A (en) 2003-11-05
GT200100075A (en) 2001-12-31
ECSP014065A (en) 2003-01-13
SV2002000440A (en) 2002-10-24
PA8516701A1 (en) 2002-09-17
PE20011256A1 (en) 2001-12-29
CA2409720A1 (en) 2001-11-15
UY26693A1 (en) 2001-12-28
US20030130303A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
AU2001248699A1 (en) A pharmaceutical composition and method of treatment of diseases of cognitive dysfuntion in a mammal
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
AU2002329990A1 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2002327792A1 (en) Diagnosis and treatment of diseases caused by mutations in cd72
AU5788300A (en) Medical treatment method and kit
AUPR638101A0 (en) Composition and method for treatment of disease
AU2002345328A1 (en) Method and device for electrochemical formation of therapeutic species in vivo
AU2002347575A1 (en) Dosing and administration of therapeutic micro-organs in living subjects and devices and methods for same
IL153824A0 (en) Method and kit for diagnosis of diseases
AU7339800A (en) Ophthalmic device and method of manufacture and use
AU2002227184A1 (en) Methods for development and use of diagnostic and therapeutic agents
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
AU4848200A (en) Intravascular device and methods of manufacture and use
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU6887101A (en) Copolymers and methods of treating prion-related diseases
PL357033A1 (en) Composition for and method of therapeutically treating human skin using a novel retinoide
AU5587800A (en) S-(+)-desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
AU2002363800A1 (en) Therapeutic agent composition and method of use
AU2001292818A1 (en) Use of transcription factors for treating inflammation and other diseases
AU2001226609A1 (en) Method and formulation for treatment of vasoconstriction
AUPQ582400A0 (en) A method of treatment and agents for use therein
AU3632899A (en) Method for the therapeutic and prophylactic treatment of dental diseases
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases